FDA Approves Adjuvant Therapy for High-Risk Renal Cell Carcinoma

The FDA has approved a new indication for sunitinib (Sutent) to include the adjuvant treatment of renal cell carcinoma in patients at high risk of disease recurrence following nephrectomy.